Tamoxifen, a non-steroidal anti-estrogen, has been used successfully for a decade as post-operative adjuvant therapy for breast cancer. Tamoxifen is generally well tolerated with few side effects, especially at the typical dose of 10 mg twice daily. However, hepatic effects have been reported after tamoxifen administration and are usually found to be cholestatic in nature. Although previous reports concentrate on tamoxifen as a probable cause of drug-induced hepatotoxicity, very little attention has been focused on the use of tamoxifen in patients with pre-existing liver dysfunction and the possible need for dose adjustment. We present the case of a 48-year-old woman with an acute exacerbation of her pre-existing liver dysfunction and subsequent elevations of tamoxifen blood levels after approximately one year of tamoxifen therapy for adjuvant treatment of breast cancer. Tamoxifen dosing was adjusted based on serum levels.
Introduction
Tamoxifen, a non-steroidal anti-estrogen that has been used successfully for a decade as post-operative adjuvant therapy for breast cancer, lengthens the diseasefree interval as well as improves survival [1] . When used as an adjunct to surgery, the usual dose of tamoxifen is 10 mg twice or three times daily. The tamoxifen dose is typically 10 mg twice daily in post-menopausal women when used in combination with other chemotherapies as an adjunct to surgery, or in the setting of positive axillary lymph nodes [2] . Tamoxifen is generally well tolerated with few side effects [2, 3] . Even at dosages up to 100 mg/m 2 twice daily, the most common side effects reported are nausea/vomiting, dizziness, and flare of bone pain [2, 4] . Hepatic effects have been reported after tamoxifen administration and are usually cholestatic in nature [5] [6] [7] . Although a possible mechanism for tamoxifen induced hepatotoxicity in rats may be the formation of stable tamoxifen-DNA adducts [8] , there is no evidence that this occurs in humans [9, 10] .
We present the case of a woman with an acute exacerbation of her pre-existing liver dysfunction and subsequent elevations of tamoxifen blood levels after approximately one year of tamoxifen therapy for adjuvant treatment of breast cancer. Tamoxifen dosing was adjusted based on serum levels.
Case report
A 48-year-old post-menopausal Caucasian female with end-stage cirrhosis was hospitalized in late 1995 for treatment of an esophageal variceal hemorrhage. Her presentation at that time was one of massive hemorrhage requiring six units of packed red blood cells. After failure of initial endoscopic sclerotherapy to control the hemorrhage, she was treated by placement of a transjugular intrahepatic portosystemic shunt (TIPS). The TIPS procedure is typically performed by an interventional radiologist and it involves placement of a stainless steel stent between the hepatic and portal veins, thereby creating a 'side to side portacaval shunt' within the liver.
Her past medical history was significant for hepatitis B infection (HBV DNA positive) and alcohol abuse, as well as intraductal adenocarcinoma of the breast diagnosed in late 1994. Adjuvant therapy with tamoxifen 10 mg orally twice daily was begun in late 1994 and was tolerated without adverse effect for almost one year. Positive margins were discovered upon initial excisional biopsy and, therefore, a re-excision with axillary lymph node dissection was performed. Initial tumor staging was limited by concerns regarding the patient's liver disease, and upon her referral for liver transplant, further oncologic staging was undertaken. This examination in November 1995 revealed a well differentiated tumor (Elston grade 5, T 2 N 0 M 0 ). Receptor analysis demonstrated tumor nuclei that were ER+ (50%) and PR+ (90%) and DNA analysis showed 8.8% S-phase. At the time of receptor analysis, her serum bilirubin was 8.3 mg/dl (SI units 141.9 umol/1), protime (PT) was 16.8 sec (INR 1.8) , and serum albumin was preserved at 3.7 mg/dl (37 g/1).
Prior to the TIPS placement, the patient's liver disease had been complicated only by intermittent and mild episodes of jaundice, fevers, and ascites during the pre-vious three years. Laboratory work up revealed gradual increases in serum bilirubin and PT over this time, but the patient had remained relatively asymptomatic with the exception of these mild exacerbations until presenting with the variceal hemorrhage.
While the TIPS was successful in terms of controlling the patient's bleeding, within one week of the procedure she developed jaundice and an abrupt worsening of her liver function tests as follows: total bilirubin 19.9 mg/dl (340.3 umol/1), aspartate aminotransferase (AST) 88 IU/1 (1.47 ukat/1), and PT 21.4 sec (INR 3.0). Alkaline phosphatase (AP) remained normal at 86 IU/1 (1.43 ukat/1). The episode of acute liver dysfunction was thought to be related to portal diversion by the TIPS and prompted a determination of the patient's tamoxifen level. At this point, the patient's tamoxifen dose of 10 mg twice daily was withheld for four days before sampling for tamoxifen plasma concentration. This first plasma level of tamoxifen was 110 ng/ml (steady-state values average from 100-150 ng/ml) [2] and the N-desmethyl tamoxifen level was 742 ng/ml (steady-state values average from 200-300 ng/ml) [2] . Upon receiving these results, concerns were raised regarding the patient's impaired tamoxifen metabolism, and the tamoxifen dose was decreased to 10 mg orally once a day. In spite of the dose reduction, over the next six weeks, her tamoxifen and N-desmethyl tamoxifen levels continued to rise to 369 and 1120 ng/ml respectively. Based on these values, her tamoxifen dosage was further reduced to 10 mg every other day. On this new regimen, her tamoxifen and N-desmethyltamoxifen elimination half-lives were calculated to be 18 and 45 days, respectively. Over the following 12 months, the patient's liver function improved and, as cholestasis resolved, the levels of tamoxifen and its metabolites decreased in kind ( Figure 1 ).
Discussion
Tamoxifen is extensively metabolized in the liver by the cytochrome P450 system (CYP) at the dimethylamino group to form N-desmethyltamoxifen (primary metabolite), didesmethyltamoxifen, and 4-hydroxytamoxifen. All of the major tamoxifen derivatives, with the exception of the 4-hydroxy metabolite, are weak antiestrogens. The 4-hydroxy metabolite, however, is 100 times more potent than tamoxifen in competing with estradiol for inhibition of MCF-7 cell growth in vitro [11] . When compared with the parent compound, both N-desmethyltamoxifen and didesmethyltamoxifen exhibit low binding affinities for the estrogen receptor in vitro and reduced capacity for competitive inhibition of estradiol-stimulated MCF-7 breast cancer cells in vitro [11] . Phase II metabolism of these compounds commonly involves glucuronidation [12] . The glucuronide conjugates of tamoxifen and its metabolites undergo 99% biliary excretion, and hepatic excretory function (measured by total bilirubin), appears to be a significant determinant of tamoxifen pharmacokinetics [13] . Figure 1 . Concentrations (ng/ml) of tamoxifen and its major metabolite N-desmethyltamoxifen, and liver function tests total bilirubin (mg/dl), and PT (seconds) over a twelve-month sampling period.
In terms of the pharmacokinetics of tamoxifen in female breast cancer patients with normal hepatic function, the distribution half-life is seven to 14 hours, while the elimination half-life is approximately seven days (range three to 21 days). Elimination half-life of N-desmethyltamoxifen is nine to 14 days [12] . In our patient, the elimination half-lives of tamoxifen and N-desmethyltamoxifen were 18 and 45 days, respectively. Although tamoxifen half-life in our patient was within the normal range for a person with normal hepatic function, the half-life of the N-desmethyl metabolite was significantly longer. Serum concentrations of the N-desmethyl metabolite are generally 1-2 times greater than the parent compound [2] . In our patient, N-desmethyltamoxifen : -tamoxifen concentration ratio was frequently > 3. Steady-state levels of tamoxifen and N-desmethyltamoxifen are generally reached within approximately four and eight weeks of continuous dosing, respectively [2] . The standard daily dose of tamoxifen is 10 mg twice daily and the mean steady-state tamoxifen concentration (C ss ) is 100-150 ng/ml [2] . Tamoxifen and its metabolites show efficient partitioning in human tissues (including the liver) with levels achieving 10-60 times those seen in the plasma [14] . Unfortunately, there is very little data on tamoxifen pharmacokinetics in patients with endstage liver disease.
Although extremely limited information exists on the use of tamoxifen in the setting of pre-existing liver dysfunction, cases of tamoxifen induced hepatotoxicity have been reported in the literature [5] [6] [7] 15] . Agrawal and Zelkowitz [6] reported a case in which tamoxifen therapy was associated with cholestatic jaundice, but the patient refused both liver biopsy and rechallenge with tamoxifen. Blackburn et al. [5] reported in 1984 the case of a woman with breast cancer and bone metastases receiving tamoxifen 10 mg orally twice daily. Within 10 weeks of starting tamoxifen, the patient began to experience nausea and vomiting, hip pain, and increasing serum bilirubin and AST. Tamoxifen was discontinued at this time. A test for hepatitis B surface antigen was negative as was an ultrasound of the liver. Liver biopsy performed in this patient 10 days after discontinuation showed swollen hepatocytes, cholestasis, and prominent Kupffer cells. The patient was also rechallenged with tamoxifen and within nine days, again exhibited nausea, vomiting, and AST elevations. Although this patient was taking both steroids and analgesics and could have had hepatic micrometastases that would not have been detectable on ultrasound, the temporal relationship with tamoxifen therapy was striking. These authors also reported two additional possible but unconfirmed cases in which tamoxifen could have caused liver damage. Maruyama et al. [15] report two cases of patients on combined therapy with tamoxifen and tegafur, a derivative of 5-FU. One patient developed chronic active hepatitis after approximately three months of tamoxifen/ tegafur therapy and the other patient developed liver cirrhosis after approximately eight months of the combination therapy. Both patients' symptoms and laboratory findings resolved four to five years after discontinuation of the treatments.
Although the previous reports concentrate on tamoxifen as a probable cause of drug-induced hepatotoxicity, very little attention has been focused on the use of tamoxifen in patients with pre-existing liver dysfunction and the possible need for dose adjustment. In terms of tamoxifen disposition in patients with moderate liver function impairment, a recent study by Peyrade et al. [13] looked at the effect of age on tamoxifen disposition. These authors found that in 36.1% of the patients studied (n = 316) with altered liver function (alterations were characterized as elevations in AP alone, gamma glutamyl transferase [GGT] alone, AP and GGT, AP or GGTand ALT or total bilirubin), tamoxifen pharmacokinetics were not obviously affected. However, these authors noted a significant reduction in the relative proportion of tamoxifen metabolites in the presence of liver dysfunction, unlike the dramatic increase in the proportion of tamoxifen metabolites seen in our patient [13] . It is important to note that the alterations in liver function found in the Peyrade study were mild and that none of the patients studied exhibited any signs of obstruction. The only other mention of tamoxifen disposition in a patient with liver disease was a case reported in 1989 by De Gregorio et al. [7] . These authors report a patient with pre-existing hepatic obstruction who developed jaundice, ascites, hepatomegaly, and elevations in total bilirubin, AP, and AST, four months after the start of tamoxifen therapy. On a 20 mg dose of tamoxifen citrate twice daily, tamoxifen and N-desmethlytamoxifen plasma levels at the time of liver dysfunction were ~ 600 ng/ml and 1000 ng/ml, respectively. Twenty-two days after cessation of tamoxifen therapy, levels declined to ~ 30 ng/ml and 200 ng/ml. This case parallels our own in that it clearly demonstrates that there is a delay in the elimination of both tamoxifen and its major metabolites in the setting of cholestasis. Cholestasis, whether due to obstruction, as in the case reported by De Gregorio et al., or to hepatic synthetic dysfunction and TIPS, as in the case we report, delays tamoxifen elimination and necessitates the modification of tamoxifen doses.
The case reported herein differs from the other case reports in that our patient exhibited acute hepatic decompensation that was temporally related to portal diversion with the TIPS. We propose two potential explanations for the relationship between the TIPS placement and the hepatic dysfunction seen in our patient. Although we assume that no changes in the patient's intestinal metabolic capacity occurred after the TIPS, the shunt could have caused portal diversion of tamoxifen away from the hepatic metabolizing enzymes, resulting in greatly increased and potentially hepatotoxic levels of the parent compound. Alternatively, the TIPS itself could have caused worsening of the patient's liver function, leading to impairment of metabolic function, and increased tamoxifen levels. Since our patient's tamoxifen levels remained high even after dose reduction and the TIPS remained patent, we conclude that the high levels of tamoxifen resulting from portal diversion rather than the TIPS itself was ultimately responsible for the hepatotoxicity.
Our case report shows that practitioners must use caution when prescribing tamoxifen in patients with advanced liver disease and/or TIPS placement. Moreover, periodic therapeutic monitoring and dose individualization of tamoxifen is arguably essential in all patients with clinically significant hepatic impairment of any etiology.
